Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Myokardia Inc Cm ST (MYOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,295,257
  • Shares Outstanding, K 46,071
  • Annual Sales, $ 33,560 K
  • Annual Income, $ -67,700 K
  • 60-Month Beta 2.32
  • Price/Sales 66.42
  • Price/Cash Flow N/A
  • Price/Book 3.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.79
  • Number of Estimates 5
  • High Estimate -0.51
  • Low Estimate -1.04
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -61.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.67 +11.52%
on 05/13/19
51.29 -2.88%
on 04/29/19
+2.13 (+4.47%)
since 04/24/19
3-Month
42.92 +16.08%
on 02/26/19
56.03 -11.08%
on 03/21/19
+6.41 (+14.77%)
since 02/22/19
52-Week
39.01 +27.71%
on 02/13/19
67.79 -26.50%
on 10/01/18
+1.57 (+3.25%)
since 05/24/18

Most Recent Stories

More News
MyoKardia (MYOK) Reports Q1 Loss, Misses Revenue Estimates

MyoKardia (MYOK) delivered earnings and revenue surprises of -43.08% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

MYOK : 49.82 (+2.98%)
MyoKardia Reports First Quarter 2019 Financial Results

Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial

MYOK : 49.82 (+2.98%)
MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos,...

MYOK : 49.82 (+2.98%)
MyoKardia Announces Inaugural MyoSeeds(TM) Research Grants Program Awardees

MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced the award of $750,000 divided among three innovative...

MYOK : 49.82 (+2.98%)
MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it will report...

MYOK : 49.82 (+2.98%)
Clinical Trial Results from MyoKardia's Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine

Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist

MYOK : 49.82 (+2.98%)
Detailed Research: Economic Perspectives on TIER REIT, MyoKardia, Radian Group, Packaging Corporation of America, Air Products and Chemicals, and ProAssurance -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TIER REIT, Inc. (NYSE:TIER),...

TIER : 27.09 (-0.55%)
APD : 204.49 (+0.14%)
MYOK : 49.82 (+2.98%)
RDN : 22.62 (+0.98%)
PKG : 91.01 (+0.98%)
PRA : 38.45 (+2.42%)
MyoKardia Announces Pricing of Public Offering of Common Stock

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an...

MYOK : 49.82 (+2.98%)
MyoKardia Announces Proposed Public Offering of Common Stock

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it has commenced...

MYOK : 49.82 (+2.98%)
MyoKardia (MYOK) in Focus: Stock Moves 7.3% Higher

MyoKardia (MYOK) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

CELC : 23.47 (+0.73%)
MYOK : 49.82 (+2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade MYOK with:

Business Summary

MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility...

See More

Key Turning Points

2nd Resistance Point 50.85
1st Resistance Point 50.34
Last Price 49.82
1st Support Level 48.97
2nd Support Level 48.11

See More

52-Week High 67.79
Fibonacci 61.8% 56.79
Fibonacci 50% 53.40
Fibonacci 38.2% 50.00
Last Price 49.82
52-Week Low 39.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar